NASDAQ:CRSP CRISPR Therapeutics (CRSP) Stock Price, News & Analysis $49.88 -0.16 (-0.32%) Closing price 04:00 PM EasternExtended Trading$50.13 +0.25 (+0.50%) As of 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About CRISPR Therapeutics Stock (NASDAQ:CRSP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CRISPR Therapeutics alerts:Sign Up Key Stats Today's Range$47.36▼$50.3350-Day Range$49.25▼$60.9052-Week Range$44.12▼$75.06Volume2.16 million shsAverage Volume1.75 million shsMarket Capitalization$4.82 billionP/E RatioN/ADividend YieldN/APrice Target$65.75Consensus RatingModerate Buy Company Overview CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing transformative gene-based medicines using CRISPR/Cas9 gene-editing technology. The company’s research programs are designed to address genetic diseases by precisely modifying DNA in cells, with applications across hematology, immunology, oncology, regenerative medicine and cardiovascular disease. Its lead commercial product is CASGEVY, an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals. CASGEVY uses CRISPR/Cas9 gene editing to treat sickle cell disease and transfusion-dependent beta thalassemia by modifying a patient’s blood stem cells before they are returned to the body. The company also maintains a pipeline of investigational therapies, including programs involving immune-cell engineering and gene-edited cell therapies. CRISPR Therapeutics was founded in 2013 based on discoveries involving CRISPR/Cas9 technology. The company has corporate operations in Zug, Switzerland, and Boston, Massachusetts, and works with partners to develop and commercialize therapies for patients in multiple international markets. Samarth Kulkarni, Ph.D., serves as chief executive officer, while scientific founder Emmanuelle Charpentier remains associated with the company’s scientific origins.AI Generated. May Contain Errors. Read More CRISPR Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks75th Percentile Overall ScoreCRSP MarketRank™: 3.729611457365 of 5 starsCRISPR Therapeutics scored higher than 75% of companies evaluated by MarketBeat, and ranked 253rd out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingCRISPR Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on 2 strong buy ratings, 9 buy ratings, 7 hold ratings, and 1 sell rating.Upside PotentialCRISPR Therapeutics has a consensus price target of $65.75, representing about 31.2% upside from its current price of $50.11.Amount of Analyst CoverageCRISPR Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about CRISPR Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for CRISPR Therapeutics are expected to grow in the coming year, from ($4.48) to ($3.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CRISPR Therapeutics is -10.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CRISPR Therapeutics is -10.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCRISPR Therapeutics has a P/B Ratio of 2.48. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about CRISPR Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted20.38% of the float of CRISPR Therapeutics has been sold short.Short Interest Ratio / Days to CoverCRISPR Therapeutics has a short interest ratio ("days to cover") of 9.58.Change versus previous monthShort interest in CRISPR Therapeutics has recently decreased by 2.05%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCRISPR Therapeutics does not currently pay a dividend.Dividend GrowthCRISPR Therapeutics does not have a long track record of dividend growth. News and Social Media4.1 / 5News Sentiment0.59 News SentimentCRISPR Therapeutics has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 21 news articles for CRISPR Therapeutics this week, compared to 9 articles on an average week.Search Interest11 people have searched for CRSP on MarketBeat in the last 30 days. This is an increase of 10% compared to the previous 30 days.MarketBeat Follows16 people have added CRISPR Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 167% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, CRISPR Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,500,337.00 in company stock.Percentage Held by Insiders5.20% of the stock of CRISPR Therapeutics is held by insiders.Percentage Held by Institutions69.20% of the stock of CRISPR Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about CRISPR Therapeutics' insider trading history. Receive CRSP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CRISPR Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CRSP Stock News HeadlinesCRISPR Therapeutics AG Announces Appointment of Andrew J. Silver as Principal Financial Officer and Principal Accounting Officer, Effective October 19, 20264 hours ago | marketscreener.comMCRISPR Therapeutics Names A.J. Silver CFO As Raju Prasad DepartsOctober 20 at 7:56 AM | rttnews.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.October 20 at 1:00 AM | Porter & Company (Ad)CRISPR Therapeutics Announces Chief Financial Officer TransitionOctober 19 at 7:49 PM | finance.yahoo.comCRISPR Therapeutics (NASDAQ:CRSP) Stock: Insider Simeon George Sells 14,514 SharesOctober 17 at 11:37 AM | insidertrades.comCRISPR Therapeutics (NASDAQ:CRSP) Stock: Insider James Kasinger Sells 1,040 SharesOctober 16, 2026 | insidertrades.comCRISPR Therapeutics (NASDAQ:CRSP) General Counsel Sells $119,479.60 in StockOctober 9, 2026 | insidertrades.comCRISPR Therapeutics (NASDAQ:CRSP) General Counsel James Kasinger Sells 10,400 Shares of StockSeptember 25, 2026 | insidertrades.comSee More Headlines CRSP Stock Analysis - Frequently Asked Questions How have CRSP shares performed this year? CRISPR Therapeutics' stock was trading at $52.44 on January 1st, 2026. Since then, CRSP stock has decreased by 4.4% and is now trading at $50.1090. How were CRISPR Therapeutics' earnings last quarter? CRISPR Therapeutics AG (NASDAQ:CRSP) released its quarterly earnings results on Tuesday, June, 30th. The company reported ($0.94) earnings per share (EPS) for the quarter. The firm earned $10.18 million during the quarter. CRISPR Therapeutics had a negative net margin of 3,368.72% and a negative trailing twelve-month return on equity of 24.39%. When did CRISPR Therapeutics IPO? CRISPR Therapeutics (CRSP) raised $64 million in an initial public offering on Wednesday, October 19th 2016. The company issued 4,000,000 shares at a price of $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays served as the underwriters for the IPO and Guggenheim Securities was co-manager. Who are CRISPR Therapeutics' major shareholders? Top institutional investors of CRISPR Therapeutics include Congress Asset Management Co. (0.12%), Green Alpha Advisors LLC (0.06%), Wealth Enhancement Trust Services Inc. (0.02%) and Vontobel Holding Ltd. (0.02%). Insiders that own company stock include Samarth Kulkarni, James R Kasinger, Naimish Patel, Ali Behbahani, Simeon George, Julianne Bruno, John Greene and Raju Prasad. View institutional ownership trends. How do I buy shares of CRISPR Therapeutics? Shares of CRSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CRISPR Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that CRISPR Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Palantir Technologies (PLTR), Micron Technology (MU), Editas Medicine (EDIT) and Block (XYZ). Company Calendar Last Earnings6/30/2026Today10/20/2026Next Earnings (Estimated)11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 2 weeks, CRSP's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CRSP CIK1674416 Webwww.crisprtx.com Phone(617) 315-4600FaxN/AEmployees393Year Founded2013Price Target and Rating Average Price Target for CRISPR Therapeutics$65.75 High Price Target$110.00 Low Price Target$9.00 Potential Upside/Downside+31.8%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage19 Analysts Profitability EPS (Trailing Twelve Months)($4.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$581.60 million Net Margins-3,368.72% Pretax Margin-3,346.08% Return on Equity-24.39% Return on Assets-18.25% Debt Debt-to-Equity Ratio0.34 Current Ratio17.85 Quick Ratio17.85 Sales & Book Value Annual Sales$3.51 million Price / Sales1,374.04 Cash FlowN/A Price / Cash FlowN/A Book Value$20.17 per share Price / Book2.47Miscellaneous Outstanding Shares96,690,000Free Float91,665,000Market Cap$4.82 billion OptionableOptionable Beta1.76 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:CRSP) was last updated on 10/20/2026 by MarketBeat.com Staff. From Our PartnersTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredBuy These Five AI Plays Before October 20Jeff Brown, founder and CEO of Brownstone Research, says a new market cycle he calls the million dollar cycle ...Brownstone Research | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | SponsoredPalantir and Wall Street are in on it…Palantir just signed a major AI deal with a company most investors have never heard of. Wall Street has pou...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CRISPR Therapeutics AG Please log in to your account or sign up in order to add this asset to your watchlist. Share CRISPR Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
